Mark E. Boulding's most recent trade in PTC Therapeutics Inc was a trade of 1,629 Common Stock done at an average price of $69.8 . Disclosure was reported to the exchange on Feb. 19, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 69.82 per share. | 19 Feb 2026 | 1,629 | 106,014 (0%) | 0% | 69.8 | 113,737 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 69.82 per share. | 19 Feb 2026 | 590 | 105,212 (0%) | 0% | 69.8 | 41,194 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 68.54 per share. | 19 Feb 2026 | 588 | 107,643 (0%) | 0% | 68.5 | 40,302 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 68.54 per share. | 19 Feb 2026 | 212 | 105,802 (0%) | 0% | 68.5 | 14,530 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 69.36 per share. | 17 Feb 2026 | 3,081 | 108,231 (0%) | 0% | 69.4 | 213,698 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.69 per share. | 17 Feb 2026 | 2,813 | 114,125 (0%) | 0% | 25.7 | 72,266 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 2,813 | 22,501 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 69.29 per share. | 17 Feb 2026 | 2,811 | 111,314 (0%) | 0% | 69.3 | 194,774 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 17 Feb 2026 | 2 | 111,312 (0%) | 0% | 70 | 140 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 76.56 per share. | 08 Jan 2026 | 2,482 | 115,177 (0%) | 0% | 76.6 | 190,022 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.46 per share. | 08 Jan 2026 | 1,521 | 112,105 (0%) | 0% | 77.5 | 117,817 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 76.45 per share. | 08 Jan 2026 | 1,286 | 113,626 (0%) | 0% | 76.5 | 98,315 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 78.71 per share. | 08 Jan 2026 | 686 | 111,419 (0%) | 0% | 78.7 | 53,995 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.07 per share. | 08 Jan 2026 | 265 | 114,912 (0%) | 0% | 77.1 | 20,424 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 79.52 per share. | 08 Jan 2026 | 107 | 111,312 (0%) | 0% | 79.5 | 8,509 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 2,625 | 751 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 06 Jan 2026 | 2,625 | 120,284 (0%) | 0% | 38.1 | 100,013 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 76.95 per share. | 06 Jan 2026 | 1,739 | 119,162 (0%) | 0% | 76.9 | 133,816 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.11 per share. | 06 Jan 2026 | 1,638 | 118,646 (0%) | 0% | 77.1 | 126,306 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.48 per share. | 06 Jan 2026 | 1,503 | 117,659 (0%) | 0% | 77.5 | 116,452 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.91 per share. | 06 Jan 2026 | 949 | 117,697 (0%) | 0% | 77.9 | 73,937 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 751 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 06 Jan 2026 | 751 | 118,410 (0%) | 0% | 38.1 | 28,613 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.10 per share. | 06 Jan 2026 | 471 | 117,939 (0%) | 0% | 77.1 | 36,314 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.92 per share. | 06 Jan 2026 | 269 | 117,670 (0%) | 0% | 77.9 | 20,960 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 78.61 per share. | 06 Jan 2026 | 38 | 117,659 (0%) | 0% | 78.6 | 2,987 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 79.00 per share. | 06 Jan 2026 | 11 | 117,659 (0%) | 0% | 79 | 869 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 42,500 | 42,500 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 17,000 | 120,901 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.42 per share. | 02 Jan 2026 | 2,266 | 123,167 (0%) | 0% | 39.4 | 89,326 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 2,266 | 9,063 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 74.92 per share. | 02 Jan 2026 | 1,123 | 122,044 (0%) | 0% | 74.9 | 84,135 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 76.10 per share. | 02 Jan 2026 | 1,035 | 121,009 (0%) | 0% | 76.1 | 78,764 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 76.79 per share. | 02 Jan 2026 | 108 | 120,901 (0%) | 0% | 76.8 | 8,293 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.69 per share. | 17 Nov 2025 | 2,812 | 106,713 (0%) | 0% | 25.7 | 72,240 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 2,812 | 25,314 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 75.64 per share. | 17 Nov 2025 | 1,843 | 104,870 (0%) | 0% | 75.6 | 139,405 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 76.53 per share. | 17 Nov 2025 | 777 | 104,093 (0%) | 0% | 76.5 | 59,464 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 77.18 per share. | 17 Nov 2025 | 192 | 103,901 (0%) | 0% | 77.2 | 14,819 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 07 Oct 2025 | 3,375 | 107,276 (0%) | 0% | 38.1 | 128,588 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2025 | 3,375 | 3,376 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 62.89 per share. | 07 Oct 2025 | 1,757 | 105,519 (0%) | 0% | 62.9 | 110,498 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 63.80 per share. | 07 Oct 2025 | 1,306 | 104,213 (0%) | 0% | 63.8 | 83,323 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 64.97 per share. | 07 Oct 2025 | 312 | 103,901 (0%) | 0% | 65.0 | 20,271 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.42 per share. | 03 Oct 2025 | 18,124 | 122,025 (0%) | 0% | 39.4 | 714,448 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 18,124 | 18,126 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 66.44 per share. | 03 Oct 2025 | 7,400 | 105,401 (0%) | 0% | 66.4 | 491,656 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 65.47 per share. | 03 Oct 2025 | 6,124 | 112,801 (0%) | 0% | 65.5 | 400,938 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 64.43 per share. | 03 Oct 2025 | 3,100 | 118,925 (0%) | 0% | 64.4 | 199,733 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 2,266 | 11,329 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 2,266 | 15,860 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 65.07 per share. | 03 Oct 2025 | 2,266 | 103,901 (0%) | 0% | 65.1 | 147,449 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.42 per share. | 03 Oct 2025 | 2,266 | 106,167 (0%) | 0% | 39.4 | 89,326 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.42 per share. | 03 Oct 2025 | 2,266 | 106,167 (0%) | 0% | 39.4 | 89,326 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2025 | 2,265 | 13,595 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.42 per share. | 03 Oct 2025 | 2,265 | 106,166 (0%) | 0% | 39.4 | 89,286 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 67.15 per share. | 03 Oct 2025 | 1,500 | 103,901 (0%) | 0% | 67.2 | 100,725 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 66.63 per share. | 03 Oct 2025 | 906 | 103,901 (0%) | 0% | 66.6 | 60,367 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 66.67 per share. | 03 Oct 2025 | 877 | 103,901 (0%) | 0% | 66.7 | 58,470 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 65.72 per share. | 03 Oct 2025 | 838 | 104,778 (0%) | 0% | 65.7 | 55,073 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 65.73 per share. | 03 Oct 2025 | 824 | 104,807 (0%) | 0% | 65.7 | 54,162 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 64.44 per share. | 03 Oct 2025 | 550 | 105,616 (0%) | 0% | 64.4 | 35,442 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 64.43 per share. | 03 Oct 2025 | 536 | 105,631 (0%) | 0% | 64.4 | 34,534 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2025 | 22,661 | 8,675 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 11 Sep 2025 | 22,661 | 126,562 (0%) | 0% | 38.1 | 863,384 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 61.33 per share. | 11 Sep 2025 | 22,117 | 104,445 (0%) | 0% | 61.3 | 1,356,436 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 11 Sep 2025 | 17,838 | 121,739 (0%) | 0% | 38.1 | 679,628 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2025 | 17,838 | 36,162 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 61.00 per share. | 11 Sep 2025 | 17,838 | 103,901 (0%) | 0% | 61 | 1,088,118 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2025 | 2,470 | 31,336 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 61.00 per share. | 11 Sep 2025 | 2,470 | 103,901 (0%) | 0% | 61 | 150,670 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 11 Sep 2025 | 2,470 | 106,371 (0%) | 0% | 38.1 | 94,107 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2025 | 2,356 | 33,806 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 61.00 per share. | 11 Sep 2025 | 2,356 | 103,901 (0%) | 0% | 61 | 143,716 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 11 Sep 2025 | 2,356 | 106,257 (0%) | 0% | 38.1 | 89,764 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2025 | 1,019 | 7,656 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 61.31 per share. | 11 Sep 2025 | 1,019 | 103,901 (0%) | 0% | 61.3 | 62,475 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 11 Sep 2025 | 1,019 | 104,920 (0%) | 0% | 38.1 | 38,824 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2025 | 905 | 6,751 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 61.21 per share. | 11 Sep 2025 | 905 | 103,901 (0%) | 0% | 61.2 | 55,395 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 11 Sep 2025 | 905 | 104,806 (0%) | 0% | 38.1 | 34,481 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 62.09 per share. | 11 Sep 2025 | 544 | 103,901 (0%) | 0% | 62.1 | 33,777 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 2,813 | 24,899 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 48.58 per share. | 15 Aug 2025 | 2,813 | 103,901 (0%) | 0% | 48.6 | 136,656 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.69 per share. | 15 Aug 2025 | 2,813 | 106,714 (0%) | 0% | 25.7 | 72,266 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 1,929 | 28,595 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.69 per share. | 15 May 2025 | 1,929 | 105,830 (0%) | 0% | 25.7 | 49,556 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 46.18 per share. | 15 May 2025 | 1,929 | 103,901 (0%) | 0% | 46.2 | 89,081 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 46.02 per share. | 15 May 2025 | 883 | 103,901 (0%) | 0% | 46.0 | 40,636 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 883 | 27,712 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.69 per share. | 15 May 2025 | 883 | 104,784 (0%) | 0% | 25.7 | 22,684 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 53.31 per share. | 12 Mar 2025 | 13,126 | 103,901 (0%) | 0% | 53.3 | 699,747 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 12 Mar 2025 | 13,126 | 117,027 (0%) | 0% | 33.0 | 433,421 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 13,126 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 12 Mar 2025 | 2,395 | 106,296 (0%) | 0% | 33.0 | 79,083 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 2,395 | 0 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 53.23 per share. | 12 Mar 2025 | 2,395 | 103,901 (0%) | 0% | 53.2 | 127,486 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 45,392 | 18,788 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Sale of securities on an exchange or to another person at price $ 53.15 per share. | 10 Mar 2025 | 45,392 | 103,901 (0%) | 0% | 53.2 | 2,412,585 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.02 per share. | 10 Mar 2025 | 45,392 | 149,293 (0%) | 0% | 33.0 | 1,498,844 | Common Stock |
| PTC Therapeutics Inc | Mark E. Boulding | EXEC. VP AND CLO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 11,398 | 4,114 | - | - | Stock Option (Right to Buy) |